Skip to main content

What the FDA labels say about taking them together

Andexanet alfa and apixaban

Andexanet alfa's FDA label of May 23, 2025 names apixaban in its warnings and precautions section, and apixaban's label names andexanet alfa too. The andexanet alfa label: “The thromboembolic and ischemic risks were assessed in 419 bleeding -patients in the ANNEXA-4 study who received ANDEXXA and were treated with apixaban or rivaroxaban.”

Check it at the source: the andexanet alfa FDA label on DailyMed (effective May 23, 2025); the apixaban FDA label on DailyMed (effective April 24, 2026, Cardinal Health 107, LLC).

What does the andexanet alfa label say about apixaban?

Andexanet alfa label, warnings and precautions

The thromboembolic and ischemic risks were assessed in 419 bleeding -patients in the ANNEXA-4 study who received ANDEXXA and were treated with apixaban or rivaroxaban.

Source: FDA drug label (ANDEXXA), AstraZeneca Pharmaceuticals LP, effective May 23, 2025 (SPL set 2d9d90a6-63e6-46ef-96ff-dd6519ae7b6c), via openFDA; the full label on DailyMed

What does the apixaban label say about andexanet alfa?

Apixaban label, warnings and precautions

Reversal of Anticoagulant Effect A specific reversal agent (andexanet alfa) antagonizing the pharmacodynamic effect of apixaban is available for adults.

Source: FDA drug label (ELIQUIS), NDA202155 (Bristol Myers Squibb), as published by Cardinal Health 107, LLC, effective April 24, 2026 (SPL set a454cd24-0c6d-46e8-b1e4-197388606175), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Andexanet alfa generic labelers
2Apixaban generic labelers
Andexanet alfaApixaban
Labeled forn/aAtrial fibrillation, Blood clots (DVT and PE), Stroke prevention
Boxed warningYesYes
Pharmacy cost (NADAC)n/a$5.52 per tablet 5 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?